EP0946539B1 - Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments - Google Patents

Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments Download PDF

Info

Publication number
EP0946539B1
EP0946539B1 EP97954929A EP97954929A EP0946539B1 EP 0946539 B1 EP0946539 B1 EP 0946539B1 EP 97954929 A EP97954929 A EP 97954929A EP 97954929 A EP97954929 A EP 97954929A EP 0946539 B1 EP0946539 B1 EP 0946539B1
Authority
EP
European Patent Office
Prior art keywords
methoxy
methylpiperazin
phenyl
benzenesulfonamide
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97954929A
Other languages
German (de)
English (en)
Other versions
EP0946539A1 (fr
Inventor
Steven Mark Bromidge
Francis David King
Paul Andrian Wyman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626377.7A external-priority patent/GB9626377D0/en
Priority claimed from GBGB9700901.3A external-priority patent/GB9700901D0/en
Priority claimed from GBGB9722757.3A external-priority patent/GB9722757D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0946539A1 publication Critical patent/EP0946539A1/fr
Application granted granted Critical
Publication of EP0946539B1 publication Critical patent/EP0946539B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C07D261/16—Benzene-sulfonamido isoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS disorders.
  • EPA 0 021 580 and EPA 0 076 072 describe sulphonamide derivatives which are disclosed as having antiarrhythmic activity.
  • a structurally distinct class of compounds has now been discovered, which have been found to have 5HT 6 receptor antagonist activity.
  • 5HT 6 receptor antagonists are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory enhancement e.g. for the treatment Alzheimers disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome).
  • the present invention therefore provides, in a first aspect, a compound of formula (I) or a salt thereof: wherein:
  • C 1-6 Alkyl groups may be straight chain or branched.
  • Preferred alkyl groups are generally methyl and ethyl.
  • P is a bicyclic heterocyclic ring
  • suitable examples include benzothiophene, quinoline or isoquinoline.
  • P is a 5 to 7-membered heterocyclic ring suitable examples include thienyl, furyl, pyrrolyl, triazolyl, diazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyrrolidinyl and pyrazinyl.
  • the heterocyclic rings can be linked to the remainder of the molecule via any suitable carbon atom or, when present, a nitrogen atom.
  • P is phenyl, thiophene, benzothiophene or naphthyl.
  • R 1 is a heterocyclic group suitable examples include those listed above.
  • R 1 is halogen or C 1-6 alkyl optionally substituted by one or more halogen atoms, for example methyl or trifluoromethyl.
  • n 0, 1, 2 or 3, particularly 1 or 2.
  • R 2 is hydrogen or C 1-6 alkyl.
  • R 2 is hydrogen.
  • R 3 /R 5 groups when R 3 /R 5 groups are linked together the two groups must be attached to adjacent carbon atoms of the phenyl ring.
  • R 3 is a group R 5 , in particular hydrogen.
  • R 4 is meta with respect to the sulphonamide linkage.
  • Optional substituents for these rings which can be present on carbon and/or nitrogen atoms, include, in particular methyl. More preferably R 4 is unsubstituted piperazine.
  • R 5 is C 1-6 alkoxy, most preferably methoxy.
  • R 5 is para with respect to the sulphonamide linkage.
  • P-A is benzo[b]thiophen-2-yl or benzo[b]thiophen-3-yl optionally substituted by one or two R 1 groups, especially 5-chloro-3-methylbenzo[2]thiophen-2-yl.
  • Particular compounds of the invention include:
  • the compounds of the formula (I) can form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • acids such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric and methanesulphonic.
  • Certain compounds of formula (I) are capable of existing in stereoisomeric forms including diastereomers and enantiomers and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates.
  • the different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis.
  • the invention also extends to any tautomeric forms and mixtures thereof.
  • the present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises the coupling of a compound of formula (II): in which R 1 , n, P, and A are as defined in formula (I) or protected derivatives thereof and L is a leaving group with a compound of formula (III): in which R 2 , R 3 , R 4 and R 5 are as defined in formula (I) or protected derivatives thereof and optionally thereafter:
  • Suitable leaving groups include halogen, in particular chloro.
  • the reaction of a compounds of formulae (II) and (III) is carried out by mixing the two reagents together, optionally in an inert solvent such as acetone. Such a reaction may be carried out in the presence of base.
  • Suitable protecting groups and methods for their attachment and removal are conventional in the art of organic chemistry, such as those described in Greene T.W. 'Protective groups in organic synthesis'New York, Wiley (1981).
  • suitable protecting groups for the piperazine group include BOC, COCCl 3 , COCF 3 and methyl the latter of which may be removed by treatment with 1-chloroethyl chloroformate according to standard procedures.
  • N-substituted piperazines can be prepared by alkylation of the appropriate NH-piperazine compound according to standard procedures.
  • compositions may be prepared conventionally by reaction with the appropriate acid or acid derivative.
  • Compounds of formula (I) and their pharmaceutically acceptable salts have 5HT 6 receptor antagonist activity and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimers disease (cognitive memory enhancement), sleep disorders (including disturbances of Circadian Rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus.
  • Compounds of the invention are also expected to be of use in the treatment of certain GI disorders such as IBS
  • the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders.
  • the invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
  • the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of the above disorders.
  • the present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • a pharmaceutical composition of the invention which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.
  • Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tabletting lubricants, disintegrants and acceptable wetting agents.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles (which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.
  • fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.
  • suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 20.0 mg, for example 0.2 to 5 mg; and such unit doses may be administered more than once a day, for example two or three a day, so that the total daily dosage is in the range of about 0.5 to 100 mg; and such therapy may extend for a number of weeks or months.
  • Examples 68-75 were prepared by the following general method from the corresponding N-methyl piperazine analogues:
  • the organic layer was dried, concentrated to a residue and purified by column chromatography on silica gel using a methanol/dichloromethane solvent gradient.
  • the hydrochloride salt of the product was prepared by dissolving the pure material from chromatography in acetone/dichloromethane and acidifying with ethereal HCI.
  • Examples 76-86 were prepared by the following general method from the appropriate N-Boc derivative (D4-D14):
  • Examples 87-94 were prepared by the following general method:
  • reaction mixture was quenched with water and then concentrated in vacuo before partitioning between saturated aqueous sodium bicarbonate and dichloromethane.
  • organic phase was dried over sodium sulphate and concentrated in vacuo .
  • the residue was purified by chromatography on silica to afford the following alkylated final compounds.
  • test compounds were dissolved in polyethylene glycol:dimethyl sulphoxide (1:1) at 1 or 10mM and diluted to 0.1mM using 5mM tris buffer (pH 7.7 @ 25°C). Dissolution was assisted by addition of 0.02ml 5M HCl plus heating to 40°C and sonication for 10 minutes. Serial dilutions of drugs in the same buffer were carried out using either a TECAN 5052 or Biomek 2000 Workstation.
  • Samples of the diluted test compounds (0.05ml) were mixed with 0.05ml of radio-ligand [ 3 H]-LSD prepared in the incubation buffer, and 0.4ml of a suspension of a preparation of the washed membranes of HeLa_5HT6 cells (acquired from Dr. D. Sibley, NIH, Bethesda, see Ref 1)(see Table 1), also in the incubation buffer.
  • the details of the incubation conditions for each assay are shown in Table 2.
  • the incubation buffer was 50mM Trizma (Sigma, UK) pH7.7 @ 25°C, 4mM MgCl 2 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

On décrit de nouveaux dérivés de sulfamique ayant une activité sur le système nerveux central (SNC), des procédés de préparation de ces nouveaux composés ainsi que leur utilisation en tant que médicaments.

Claims (16)

  1. Composé de formule (I) ou un de ses sels :
    Figure 00490001
       formule dans laquelle :
    P représente un groupe phényle, un groupe naphtyle, un noyau hétérocyclique bicyclique ou un noyau hétérocyclique penta- à heptagonal, chacun contenant 1 à 4 hétéroatomes choisis entre l'oxygène, l'azote et le soufre ;
    A représente une liaison simple, un groupe alkylène en C1 à C6 ou alcénylène en C1 à C6 ;
    R1 représente un atome d'halogène, un groupe alkyle en C1 à C6 facultativement substitué avec un ou plusieurs atomes d'halogène, cycloalkyle en C3 à C6, CO(alkyle en C1 à C6), alkoxy en C1 à C6, OCF3, hydroxy, hydroxyalkyle en C1 à C6, hydroxyalkoxy en C1 à C6, (alkoxy en C1 à C6) (alkoxy en C1 à C6), nitro, amino, alkylamino en C1 à C6 ou di(alkyle en C1 à C6)amino, cyano, ou bien R1 représente un groupe phényle, un groupe naphtyle, un noyau hétérocyclique bicyclique ou un noyau hétérocyclique penta- à heptagonal, chacun contenant 1 à 4 hétéroatomes choisis entre l'oxygène, l'azote et le soufre ;
    n est égal à 0, 1, 2, 3, 4, 5 ou 6 ;
    R2 représente un atome d'hydrogène, un groupe alkyle en C1 à C6 ou aryl(alkyle en C1 à C6) ;
    R3 représente un groupe R5 ou, conjointement avec R5, forme un groupe (CH2)2O ou (CH2)3O, ou bien R3 est lié à R2 pour former un groupe (CH2)2 ou (CH2)3 ;
    R4 représente un noyau N-pipérazine facultativement substitué avec un substituant alkyle en C1 à C6 ; et
    R5 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle en C1 à C6, cycloalkyle en C3 à C6, CO(alkyle en C1 à C6), alkoxy en C1 à C6, hydroxy, hydroxyalkyle en C1 à C6, hydroxyalkoxy en C1 à C6, (alkoxy en C1 à C6) (alkoxy en C1 à C6), nitro, trifluorométhyle, cyano ou aryle ;
       le terme aryle représentant un groupe phényle ou naphtyle.
  2. Composé suivant la revendication 1, dans lequel P représente un groupe phényle, thiophène, benzothiophène ou naphtyle.
  3. Composé suivant la revendication 1 ou 2, dans lequel R1 représente un atome d'halogène ou un groupe alkyle en C1 à C6 facultativement substitué avec un ou plusieurs atomes d'halogène.
  4. Composé suivant l'une quelconque des revendications 1 à 3, dans lequel R2 représente un atome d'hydrogène.
  5. Composé suivant l'une quelconque des revendications 1 à 4, dans lequel R4 représente un noyau pipérazine non substitué.
  6. Composé suivant l'une quelconque des revendications 1 à 5, dans lequel R5 représente un groupe alkoxy en C1 à C6.
  7. Composé suivant l'une quelconque des revendications 1 à 6, dans lequel R5 est en position para par rapport à la liaison sulfonamide.
  8. Composé suivant l'une quelconque des revendications 1 à 7, dans lequel P-A représente un groupe 5-chloro-3-méthylbenzo[2]thiophène-2-yle.
  9. Composé suivant la revendication 1, qui consiste en :
    4-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-5-(pyridine-2-yl)-2-thiophènesulfonamide,
    2,5-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-thiophènesulfonamide,
    4-bromo-5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-benzènesulfonamide,
    3-bromo-5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-thiophènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzylsulfonamide,
    2-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3-bromo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-trans-styrènesulfonamide,
    3,4-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3,5-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-[2,1,3]benzothiadiazole-4-sulfonamide,
    5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-méthyl-2-benzothiophènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-méthyl-5-nitrobenzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-2-trifluorométhylbenzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl)-3-trifluorométhylbenzènesulfonamide,
    2,5-diméthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    4-fluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-éthyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-tertio-butyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl) -phényl]benzènesulfonamide,
    4-isopropyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,.
    4-tertio-amyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-4-trifluorométhoxybenzènesulfonamide,
    4-n-butoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
    5-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-thiophènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-1-naphtalènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-naphtalènesulfonamide,
    5-(diméthylamino)-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]-1-naphtalènesulfonamide,
    4-bromo-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    4-méthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-n-butyl-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-amino-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    2-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    2, 3, 4-trichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2,5-diméthylbenzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-méthylbenzènesulfonamide,
    2,5-dibromo-3,6-difluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2,3,5,6-tétraméthylbenzènesulfonamide,
    5-chloro-2-méthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    3-fluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3,4-difluoro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    4-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3-nitrobenzènesulfonamide,
    3-chloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-méthylbenzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-8-quinoléinesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-phénylbenzènesulfonamide,
    3,4-diméthoxy-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]benzènesulfonamide,
    N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-3,5-diméthyl-4-isoxazolesulfonamide,
    4-bromo-N-[4-méthoxy-3-(4-éthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    2,3-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    5-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-2-méthylbenzènesulfonamide,
    3-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    3-iodo-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]-4-méthylbenzènesulfonamide,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloronaphtalène-2-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloronaphtalène-1-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 4-chloronaphtalène-1-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 7-chloronaphtalène-1-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-2-méthylbenzo[b]thiophène-3-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide benzofuranne-2-sulfonique,
    [4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 1-méthyl-lH-indole-2-sulfonique,
    [4-méthoxy-3-pipérazine-1-ylphényl]amide d'acide 5-pyridine-2-ylthiophène-2-sulfonique,
    N-(4-méthoxy-3-pipérazine-1-ylphényl)-3-trifluorométhylbenzènesulfonamide,
    3-iodo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 3,5-diméthylisoxazole-4-sulfonique,
    3,5-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    2,5-dibromo-3,6-difluoro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide naphtalène-1-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 2-bromo-5-chlorothiophène-2-sulfonique,
    2-chloro-4-fluoro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    3-bromo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    3-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloronaphtalène-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 4-bromo-5-chlorothiophène-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 2,5-dichlorothiophène-3-sulfonique,
    4-bromo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloro-2-méthylbenzo[b]thiophène-3-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 1-méthyl-1H-indole-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide benzofuranne-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide naphtalène-2-sulfonique,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-chloronaphtalène-1-sulfonique,
    4-chloro-2,5-diméthyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    3,4-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    3-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-4-méthylbenzènesulfonamide,
    2-trifluorométhyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    4-iodo-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    4-tertio-butyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide naphtalène-1-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide thiophène-2-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-chlorothiophène-2-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-pyridine-2-ylthiophène-2-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl)amide d'acide 2,5-dichlorothiophène-3-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 4-bromo-5-chlorothiophène-2-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 3-bromo-5-chlorothiophène-2-sulfonique,
    4-chloro-2,5-diméthyl-N- [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]amide d'acide naphtalène-2-sulfonique,
    3-bromo-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    3,5-dichloro-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    4-tertio-butyl-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    2,5-dibromo-3,6-difluoro-N-[7-(4-méthylpipérazine-1-yl)-2,3-dihydrobenzofuranne-5-yl]benzènesulfonamide,
    2,5-dibromo-3,6-difluoro-N-(7-pipérazine-1-yl-2,3-dihydrobenzofuranne-5-yl)benzènesulfonamide,
    4-chloro-2,5-diméthyl-N-(7-pipérazine-1-yl-2,3-dihydrobenzofuranne-5-yl)benzènesulfonamide,
    [4-hydroxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [4-éthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [4-isopropoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [2-bromo-5-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphtalène-2-sulfonique,
    [4-chloro-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [4-bromo-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphtalène-2-sulfonique,
    1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-6-(4-méthylpipérazine-1-yl)-2,3-dihydro-lH-indole,
    1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-méthoxy-6-(4-méthylpipérazine-1-yl)-2,3-dihydro-lH-indole,
    [4-méthoxy-2-méthyl-3-(4-méthylpipérazine-1-yl)-phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [2-(2-hydroxyéthyl)-4-méthoxy-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    chlorhydrate de 1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-méthoxy-4-(4-méthylpipérazine-1-yl)-2,3-dihydro-1H-indole,
    [3-méthoxy-4-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
    [3-(4-méthylpipérazine-1-yl)phényl]amide d'acide naphtalène-2-sulfonique,
    2,3,4-trichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    2,3-dichloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    3-chloro-2-méthyl-N-(4-méthoxy-3-pipérazine-1-ylphényl)benzènesulfonamide,
    4-chloro-N-(4-méthoxy-3-pipérazine-1-ylphényl)-benzènesulfonamide,
    (4-méthoxy-3-pipérazine-1-ylphényl)amide d'acide 5-bromothiophène-2-sulfonique,
    2,3-dichloro-N-[4-méthoxy-3-(4-méthylpipérazine-1-yl)-phényl]benzènesulfonamide,
    1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-5-phényl-6-pipérazine-1-yl-2,3-dihydro-lH-indole,
    5-chloro-1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-6-pipérazine-1-yl-2,3-dihydro-1H-indole,
    1-(5-chloro-3-méthylbenzo[b]thiophène-2-sulfonyl)-7-pipérazine-1-yl-1,2,3,4-tétrahydroquinoléine,
    [4-méthyl-3-(4-méthylpipérazine-1-yl)phényl]amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique,
       et ses sels pharmaceutiquement acceptables.
  10. Composé suivant l'une quelconque des revendications 1 à 8, qui est le chlorhydrate de (4-méthoxy-3-pipérazine-1-yl)phényl)amide d'acide 5-chloro-3-méthylbenzo[b]thiophène-2-sulfonique.
  11. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé en thérapeutique.
  12. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé en thérapeutique, dans lequel l'activité bénéfique se manifeste par un antagonisme des récepteurs 5-HT6.
  13. Composé suivant l'une quelconque des revendications 1 à 10, destiné à être utilisé dans le traitement de la schizophrénie, de la maladie d'Alzheimer et/ou de la dépression.
  14. Composition pharmaceutique qui comprend un composé suivant l'une quelconque des revendications 1 à 10 et un support ou excipient pharmaceutiquement acceptable.
  15. Utilisation d'un composé suivant l'une quelconque des revendications 1 à 10 dans la production d'un médicament destiné au traitement de la schizophrénie, de la maladie d'Alzheimer et/ou de la dépression.
  16. Procédé pour la préparation d'un composé de formule (I) ou d'un de ses sels répondant à la définition suivant la revendication 1, qui comprend le couplage d'un composé de formule (II) :
    Figure 00590001
       dans laquelle R1, n, P et A sont tels que définis dans la formule (I), ou leurs dérivés protégés, et L représente un groupe partant, avec un composé de formule (III) :
    Figure 00590002
       dans laquelle R2, R3, R4 et R5 sont tels que définis dans la formule (I), ou leurs dérivés protégés, et ensuite, facultativement :
    l'élimination de tous les groupes protecteurs
    l'interconversion de composés de formule (I) dans laquelle R4 représente un groupe NH-pipérazine en composés de formule (I) dans laquelle R4 représente un groupe N-(alkyle en C1 à C6)pipérazine par alkylation,
    la formation d'un sel pharmaceutiquement acceptable.
EP97954929A 1996-12-19 1997-12-15 Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments Expired - Lifetime EP0946539B1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9626377.7A GB9626377D0 (en) 1996-12-19 1996-12-19 Novel compounds
GB9626377 1996-12-19
GBGB9700901.3A GB9700901D0 (en) 1997-01-17 1997-01-17 Novel compounds
GB9700901 1997-01-17
GBGB9722757.3A GB9722757D0 (en) 1997-10-27 1997-10-27 Novel compounds
GB9722757 1997-10-27
PCT/EP1997/007159 WO1998027081A1 (fr) 1996-12-19 1997-12-15 Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments

Publications (2)

Publication Number Publication Date
EP0946539A1 EP0946539A1 (fr) 1999-10-06
EP0946539B1 true EP0946539B1 (fr) 2003-08-13

Family

ID=27268644

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97954929A Expired - Lifetime EP0946539B1 (fr) 1996-12-19 1997-12-15 Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments

Country Status (31)

Country Link
US (2) US6423717B1 (fr)
EP (1) EP0946539B1 (fr)
JP (1) JP2001506646A (fr)
KR (1) KR20000069554A (fr)
CN (1) CN1246116A (fr)
AP (1) AP1277A (fr)
AR (1) AR010795A1 (fr)
AT (1) ATE247099T1 (fr)
AU (1) AU729056B2 (fr)
BG (1) BG103530A (fr)
BR (1) BR9713734A (fr)
CA (1) CA2275492A1 (fr)
CZ (1) CZ220399A3 (fr)
DE (1) DE69724142T2 (fr)
DZ (1) DZ2376A1 (fr)
EA (1) EA002351B1 (fr)
ES (1) ES2203831T3 (fr)
HU (1) HUP0000658A3 (fr)
ID (1) ID22821A (fr)
IL (1) IL130297A0 (fr)
MA (1) MA24426A1 (fr)
NO (1) NO993003D0 (fr)
NZ (1) NZ335970A (fr)
OA (1) OA11066A (fr)
PE (1) PE46899A1 (fr)
PL (1) PL334337A1 (fr)
SK (1) SK80899A3 (fr)
TR (1) TR199901361T2 (fr)
TW (1) TW418205B (fr)
UY (1) UY24819A1 (fr)
WO (1) WO1998027081A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
HUP0003073A3 (en) 1997-07-11 2002-10-28 Smithkline Beecham Plc Benzenesulfonamide derivatives, process for producing them and their use as medicines
ES2317688T3 (es) 1998-01-29 2009-04-16 Amgen Inc. Moduladores ppar-gamma.
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
GB9810671D0 (en) * 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9818916D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9818914D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9820113D0 (en) 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001045694A1 (fr) * 1999-12-21 2001-06-28 Smithkline Beecham Corporation Antagonistes des recepteurs de l'urotensine ii
SE9904723D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
SE0002739D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New use
US6818639B2 (en) 2000-07-21 2004-11-16 Biovitrum Ab Pharmaceutical combination formulation and method of treatment with the combination
US6399617B1 (en) 2000-07-21 2002-06-04 Biovitrum Ab Use
US7071220B2 (en) 2000-09-18 2006-07-04 Toa Eiyo Ltd. N-substituted benzothiophenesulfonamide derivatives
CN1245400C (zh) * 2000-09-18 2006-03-15 东亚荣养株式会社 N－取代苯并噻唑磺胺衍生物
US7034029B2 (en) 2000-11-02 2006-04-25 Wyeth 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
WO2002042293A1 (fr) * 2000-11-21 2002-05-30 Smithkline Beecham P.L.C. Derives d'isoquinoleine utiles pour le traitement de troubles du systeme nerveux central
CA2432713C (fr) 2000-12-22 2009-10-27 Ishihara Sangyo Kaisha, Ltd. Derives d'aniline ou sels de ceux-ci, ainsi qu'inhibiteurs de production de cytokine contenant ces derives
WO2002088101A2 (fr) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
AR033879A1 (es) 2001-05-07 2004-01-07 Smithkline Beecham Corp Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto
EP1387679A4 (fr) * 2001-05-07 2004-08-11 Smithkline Beecham Corp Sulfonamides
EP1399137A4 (fr) * 2001-05-07 2005-12-14 Smithkline Beecham Corp Sulfonamides
EP1385495A4 (fr) * 2001-05-07 2005-12-21 Smithkline Beecham Corp Sulfonamides
EP1385830A4 (fr) * 2001-05-07 2005-08-17 Smithkline Beecham Corp Sulfonamides
US6743796B2 (en) * 2001-05-07 2004-06-01 Wyeth Piperazinyl-isatins
GB0111186D0 (en) * 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
KR100922486B1 (ko) * 2001-05-11 2009-10-20 바이오비트럼 에이비(피유비엘) 비만, 제 ⅱ 형 당뇨병 및 ｃｎｓ 장애의 치료를 위한신규한 아릴술폰아미드 화합물
MXPA03010232A (es) 2001-05-11 2004-03-16 Biovitrum Ab Compuestos de arilsulfonamida, para el tratamiento de la obesidad, de la diabetes tipo ii y de trastornos del sistema nervioso central.
US7718650B2 (en) 2001-05-11 2010-05-18 Biovitrum Ab Aryl sulfonamide compounds for treating obesity
WO2002098857A1 (fr) 2001-06-07 2002-12-12 F. Hoffmann-La Roche Ag Nouveaux derives de l'indole a affinite pour le recepteur 5-ht6
US7144883B2 (en) * 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
MXPA03011638A (es) 2001-06-15 2004-04-02 Hoffmann La Roche Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
US6727264B1 (en) 2001-07-05 2004-04-27 Synaptic Pharmaceutical Corporation Substituted anilinic piperidines as MCH selective antagonists
JP2005527463A (ja) * 2001-08-07 2005-09-15 スミスクライン　ビーチャム　パブリック　リミテッド　カンパニー Ｃｎｓ疾患を治療するための５−ｈｔ６受容体アフィニティーを有する３−アリールスルホニル−７−ピペラジニル−インドール、−ベンゾフランおよび−ベンゾチオフェン
PL373397A1 (en) * 2001-08-10 2005-08-22 F.Hoffmann-La Roche Ag Arylsulfonyl derivatives with 5-ht6 receptor affinity
JP4221294B2 (ja) 2001-09-05 2009-02-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 摂食亢進剤および食欲不振症治療剤
SE0103644D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic isoquinoline compounds
ATE429916T1 (de) * 2001-11-09 2009-05-15 Biovitrum Ab Publ Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
RS44204A (en) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RS44304A (en) 2001-11-22 2007-06-04 Biovitrum Ab., Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2005516903A (ja) * 2001-11-30 2005-06-09 エフ．ホフマン−ラ　ロシュ　アーゲー 喘息の処置におけるｃｃｒ−３受容体拮抗物質として使用するためのピペラジン誘導体
AU2003203148A1 (en) * 2002-02-05 2003-09-02 High Point Pharmaceuticals, Llc Novel aryl- and heteroarylpiperazines
US20070270432A1 (en) * 2002-02-05 2007-11-22 James Hagan Novel Method
BR0307557A (pt) * 2002-02-13 2005-01-04 Glaxo Group Ltd Derivados benzenosulfonamida como agentes antipsicóticos
US20050085461A1 (en) * 2002-02-13 2005-04-21 Cooper David G. Benzenesulfonamide derivatives
DE60304695T2 (de) * 2002-02-13 2006-09-21 Glaxo Group Ltd., Greenford 7-arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo[d]azepin-derivate mit 5-hat-6-rezeptor affinität zur behandlung von erkrankungen des zentralnervensystems
DK1497266T3 (da) 2002-03-27 2008-10-06 Glaxo Group Ltd Quinolinderivater og deres anvendelse som 5HT6-ligander
US20040142948A1 (en) * 2002-05-07 2004-07-22 Dashyant Dhanak Sulfonamides
MXPA04011254A (es) * 2002-05-13 2005-01-25 Hoffmann La Roche Derivados de benzoxazina como moduladores de 5-hidroxitriptamina 6 (5-ht6) y usos de los mismos.
EP1897876A3 (fr) 2002-06-20 2009-03-18 Biovitrum AB (publ) Composés utiles pour le traitement de l'obésité, du diabète de type II et des troubles du système nerveux central
SG156524A1 (en) * 2002-06-20 2009-11-26 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
JP4754821B2 (ja) * 2002-06-20 2011-08-24 プロキシマゲン・リミテッド 肥満症、ｉｉ型糖尿病およびｃｎｓ障害の治療に有用な新規化合物
ES2274285T3 (es) 2002-10-18 2007-05-16 F. Hoffmann-La Roche Ag 4-piperanzinilbencenosulfonilindoles con afinidad al receptor 5-ht6.
WO2004043369A2 (fr) * 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
WO2004043368A2 (fr) * 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
WO2004072087A2 (fr) * 2003-02-13 2004-08-26 Lanxess Deutschland Gmbh Complexes metalliques servant de composes photoabsorbants dans la couche d'information de supports de donnees optiques
AU2004212985B2 (en) * 2003-02-20 2010-10-14 Encysive Pharmaceuticals Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
TWI289141B (en) 2003-03-11 2007-11-01 Hoffmann La Roche F. Ag. Quinolinone derivatives and uses thereof
US7262197B2 (en) * 2003-03-31 2007-08-28 Janssen Pharmaceutica, N.V Phospholipase C inhibitors for use in treating inflammatory disorders
US6946466B2 (en) * 2003-04-10 2005-09-20 Schering Ag Aromatic sulfonamides as peroxynitrite-rearrangement catalysts
US20040204422A1 (en) * 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0320320D0 (en) * 2003-08-29 2003-10-01 Glaxo Group Ltd Novel compounds
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
BRPI0417833A (pt) * 2003-12-19 2007-04-17 Biovitrum Ab novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6
SE0303480D0 (sv) * 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
CA2575359A1 (fr) * 2004-07-28 2006-02-02 Glaxo Group Limited Derives de piperazine convenant pour le traitement de troubles gastro-intestinaux
CN101031338B (zh) * 2004-09-30 2013-01-02 弗·哈夫曼-拉罗切有限公司 治疗认知障碍的组合物和方法
WO2006040176A1 (fr) 2004-10-14 2006-04-20 Abbott Gmbh & Co. Kg Composes d'azabicycloheptyle destines au traitement des troubles reagissant a une modulation du recepteur de dopamine d3
AU2005293698B2 (en) 2004-10-14 2011-12-15 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
WO2006062481A1 (fr) * 2004-12-09 2006-06-15 Biovitrum Ab Nouveaux derives de benzofurane et leur utilisation dans le traitement de l'obesite, du diabete de type 2 et des troubles du systeme nerveux central
EP1676841A1 (fr) * 2004-12-30 2006-07-05 Esteve Laboratorios Dr. Esteve S.A. Composés substitués type sulphonamide d'indazole ou sulphonamide de 2,3-dihydroindole, leur préparation et leur utilisation comme médicaments
WO2006075808A1 (fr) * 2005-01-12 2006-07-20 Inje University Composition pharmaceutique comprenant un inhibiteur de p25/cdk5 permettant de prevenir ou de traiter une maladie neurodegenerative
EP2386554A1 (fr) 2005-07-04 2011-11-16 High Point Pharmaceuticals, LLC Composés actives sur le recepteur histamine H3
US7998981B2 (en) 2005-08-12 2011-08-16 Suven Life Sciences Limited Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands
US7923566B2 (en) 2005-08-16 2011-04-12 Suven Life Sciences Limited Alternative process for the preparation of losartan
US20100048713A1 (en) * 2006-01-06 2010-02-25 Aarhus Universitet Compounds acting on the serotonin transporter
AR060213A1 (es) 2006-03-31 2008-06-04 Glaxo Group Ltd Compuesto de piperazinil - piridinil -bencensulfonamida , su uso para fabricar un medicamento proceso para la preparacion del mismo composicion farmaceutica que lo comprende y proceso para prepararla
UY30295A1 (es) * 2006-04-19 2007-11-30 Abbott Gmbh & Amp Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6
EP2074110A1 (fr) 2006-04-19 2009-07-01 Abbott GmbH & Co. KG Composés hétérocycliques pouvant être utilisés pour traiter des troubles qui répondent à la modulation du récepteur de sérotonine 5ht6
WO2007135111A1 (fr) 2006-05-23 2007-11-29 High Point Pharmaceuticals, Llc Nouveaux médicaments
EP2079732B9 (fr) 2006-05-29 2012-03-21 High Point Pharmaceuticals, LLC 3-(1,3-benzodioxol-5-yl)-6-(4-cyclopropylpiperazin-1-yl)-pyradine, ses sels et solvates et son utilisation comme antagoniste du recepteur d'histamin h3
CA2669117A1 (fr) 2006-10-26 2008-05-02 Gary A. Flynn Modulateurs d'aquaporine et procedes pour leur utilisation pour le traitement d'un oedeme et d'un desequilibre de fluides
ATE491685T1 (de) 2007-01-08 2011-01-15 Suven Life Sciences Ltd 5-(heterocyclyl)alkyl-n- (arylsulfonyl)indolverbindungen und ihre verwendung als 5-ht6-liganden
EP2118062A1 (fr) 2007-01-10 2009-11-18 F. Hoffmann-Roche AG Dérivés de sulfonamide en tant qu'inhibiteurs de la chymase
CA2681034A1 (fr) 2007-03-23 2008-10-02 Abbott Gmbh & Co. Kg Composes azetidine appropries pour traiter des troubles qui repondent a la modulation du recepteur 5-ht<sb>6</sb> de la serotonine
DK2155674T3 (da) 2007-05-03 2011-09-26 Suven Life Sciences Ltd Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander
EP2014656A3 (fr) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Nouveaux antagonistes d'hétéocycliques h3
ES2359170T3 (es) * 2007-07-19 2011-05-19 Laboratorios Del Dr. Esteve S.A. Compuestos tetrahidro-quinolín-sulfonamida sustituidos, su preparación y uso como medicamentos.
AU2008315309B2 (en) 2007-10-26 2011-06-09 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
PA8802201A1 (es) * 2007-11-02 2009-06-23 Abbott Gmbh & Co Kg Compuestos de bencensulfonalida apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5-ht6
US9084742B2 (en) 2007-12-12 2015-07-21 Axovant Sciences Ltd. Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-Quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
KR20110017432A (ko) * 2008-06-11 2011-02-21 아이알엠 엘엘씨 말라리아의 치료에 유용한 화합물 및 조성물
CA2737282C (fr) 2008-09-17 2014-03-25 Suven Life Sciences Limited Composes amines d'arylsulfonamide et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
WO2010032257A1 (fr) 2008-09-17 2010-03-25 Suven Life Sciences Limited Composés arylindolylsulfonamides et leur utilisation en tant que ligands de 5-ht<sb>6</sb>
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
KR101073703B1 (ko) 2009-04-07 2011-10-14 한국화학연구원 피페라진 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 중추신경계 질환의 예방 또는 치료용 약학적 조성물
SG175187A1 (en) 2009-04-30 2011-11-28 Abbott Gmbh & Co Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor
WO2010125136A1 (fr) * 2009-04-30 2010-11-04 Abbott Gmbh & Co. Kg Composés de benzenesulfonanilide pour le traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine
US8343959B2 (en) 2009-04-30 2013-01-01 Abbott Gmbh & Co. Kg N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor
EP2424844A1 (fr) * 2009-04-30 2012-03-07 Abbott GmbH & Co. KG Composés de benzènesulfonanilide pour le traitement de troubles répondant à la modulation du récepteur 5-ht6 de la sérotonine
EA022043B1 (ru) 2010-01-05 2015-10-30 Сувен Лайф Сайенсиз Лимитед Сульфоновые соединения в качестве лигандов 5-htрецептора
WO2012040279A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
WO2012059431A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type benzènesulfonyle ou sulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6 de la sérotonine
WO2012059432A1 (fr) 2010-11-01 2012-05-10 Abbott Gmbh & Co. Kg Composés de type n-phényl-(homo)pipérazinyl-benzènesulfonyle ou benzènesulfonamide appropriés pour le traitement de troubles qui répondent à la modulation du récepteur 5-ht6
ES2413911B1 (es) * 2011-12-15 2014-05-14 Universidad De Zaragoza Agente inhibidor de la agregación del peptido beta amiloide.
CN104220421A (zh) 2012-03-20 2014-12-17 阿达梅德公司 用于治疗中枢神经系统疾病的苄胺的磺酰胺衍生物
CA2905993C (fr) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Derives de 4-amino-pyrimidinyle-2-amino-phenyle substitues et compositions pharmaceutiques a base de ceux-ci en tant qu'inhibiteurs dejak2 et d'alk2
SI3027613T1 (sl) 2013-07-25 2018-10-30 Uniwersytet Jagiellonski Derivati pirolokvinolina kot 5-HT6 antagonisti, postopek priprave in uporabe le-teh
US9840482B2 (en) 2014-04-19 2017-12-12 Sunshine Lake Pharma Co., Ltd. Sulfonamide derivatives and pharmaceutical applications thereof
CN105367472B (zh) * 2014-08-12 2020-04-21 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
CN105367473B (zh) * 2014-08-12 2020-02-11 广东东阳光药业有限公司 吲哚啉类衍生物及其在药物上的应用
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
KR20180022792A (ko) 2015-06-12 2018-03-06 엑소반트 사이언시즈 게엠베하 렘 수면 행동 장애의 예방 및 치료에 유용한 디아릴 및 아릴헤테로아릴 우레아 유도체
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
BR112018000728A2 (pt) 2015-07-15 2018-09-04 Axovant Sciences Gmbh resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo
CN108926565A (zh) * 2017-05-26 2018-12-04 中国科学院上海生命科学研究院 五羟色胺受体亚型6小分子激活剂及拮抗剂在防治阿尔茨海默症中的应用
WO2019180176A1 (fr) 2018-03-21 2019-09-26 Spherium Biomed, S.L. Composition pour le traitement de la schizophrénie et/ou de la psychose
MX2021000977A (es) 2018-07-26 2021-04-12 Sumitomo Pharma Oncology Inc Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE81861C (fr)
NZ193654A (en) * 1979-05-16 1984-08-24 Wuelfing Johann A Naphthalene sulphonamido-alkyl-piperidines,pyrrolidines or piperazines and pharmaceutical compositions
US4315014A (en) * 1980-09-24 1982-02-09 Warner-Lambert Company Antibacterial amide compounds and pharmaceutical composition containing the same
DE3276313D1 (en) * 1981-09-24 1987-06-19 Beecham Wuelfing Gmbh & Co Kg Sulphonamides
CN85106905A (zh) * 1985-08-08 1987-02-04 Fmc公司 含有1-芳基-δ2-1，2，4，-三唑啉-5-酮类的除草剂及其制备方法
AU5175490A (en) * 1989-02-27 1990-09-26 Du Pont Merck Pharmaceutical Company, The Novel sulfonamides as radiosensitizers
JPH04330057A (ja) * 1991-05-01 1992-11-18 Hiroyoshi Hidaka アニリンアリールスルホン酸アミド類及び薬剤として許容され得るその酸付加塩
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
DE4206531A1 (de) * 1992-03-02 1993-09-09 Bayer Ag N-aryl-stickstoffheterocyclen
DE4303376A1 (de) * 1993-02-05 1994-08-11 Bayer Ag Substituierte Triazolinone
JP3328936B2 (ja) * 1993-09-03 2002-09-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ１ｄレセプター拮抗薬用インドールおよびインドリン誘導体
WO1995011243A1 (fr) * 1993-10-19 1995-04-27 Smithkline Beecham Plc Derives de benzanilide en tant qu'antagonistes du recepteur de 5ht-1d
WO1995015954A1 (fr) * 1993-12-07 1995-06-15 Smithkline Beecham Plc Biphenylylamides heterocycliques utilisables comme antagonistes du 5ht1d
WO1995032967A1 (fr) * 1994-05-28 1995-12-07 Smithkline Beecham Plc Derives amide a activite antagoniste par rapport a 5ht1d
US5939451A (en) 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
DZ2376A1 (fr) * 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153858B2 (en) 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds

Also Published As

Publication number Publication date
TW418205B (en) 2001-01-11
US20030069233A1 (en) 2003-04-10
JP2001506646A (ja) 2001-05-22
NZ335970A (en) 2001-10-26
PE46899A1 (es) 1999-06-24
US6423717B1 (en) 2002-07-23
BG103530A (bg) 2000-01-31
AU729056B2 (en) 2001-01-25
TR199901361T2 (xx) 1999-08-23
DZ2376A1 (fr) 2002-12-28
SK80899A3 (en) 2000-02-14
ATE247099T1 (de) 2003-08-15
DE69724142D1 (de) 2003-09-18
AU6090498A (en) 1998-07-15
AR010795A1 (es) 2000-07-12
CZ220399A3 (cs) 1999-11-17
WO1998027081A1 (fr) 1998-06-25
AP9901556A0 (en) 1999-06-30
HUP0000658A2 (hu) 2001-02-28
IL130297A0 (en) 2000-06-01
NO993003L (no) 1999-06-18
DE69724142T2 (de) 2004-06-03
CA2275492A1 (fr) 1998-06-25
PL334337A1 (en) 2000-02-28
EA002351B1 (ru) 2002-04-25
ES2203831T3 (es) 2004-04-16
MA24426A1 (fr) 1998-07-01
EA199900561A1 (ru) 2000-02-28
NO993003D0 (no) 1999-06-18
HUP0000658A3 (en) 2001-03-28
UY24819A1 (es) 2001-08-27
EP0946539A1 (fr) 1999-10-06
BR9713734A (pt) 2000-03-28
CN1246116A (zh) 2000-03-01
AP1277A (en) 2004-05-05
KR20000069554A (ko) 2000-11-25
OA11066A (en) 2003-03-10
US6599904B2 (en) 2003-07-29
ID22821A (id) 1999-12-09

Similar Documents

Publication Publication Date Title
EP0946539B1 (fr) Derives de sulfamide, procede de preparation de ces derives et utilisation de ces derniers en tant que medicaments
US6316450B1 (en) Compounds
US7572787B2 (en) Substituted naphthalene sulfonamides
US20040242589A1 (en) 3-arylsulfonyl-7-piperzinyl-indoles-benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
US20030149019A1 (en) New compounds
AU2002309435A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes
EP1049679A2 (fr) Derivees d&#39;sulfonamides pour traitment d&#39;irritationes d&#39;systeme nerveux central
CA2274055A1 (fr) Derives du n-piperazine-1-ylphenyl-benzamide
US20040132742A1 (en) Novel compounds
MXPA99005900A (en) Sulphonamide derivatives, process for their preparation, and their use as medicaments

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990607

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 19990607;SI PAYMENT 19990607

17Q First examination report despatched

Effective date: 20010418

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

AK Designated contracting states

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: RO SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030813

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030813

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030813

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030813

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20030813

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69724142

Country of ref document: DE

Date of ref document: 20030918

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031113

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031215

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20031231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040113

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2203831

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040514

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20051104

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20051201

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20051216

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20051230

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060113

Year of fee payment: 9

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1022915

Country of ref document: HK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061231

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070703

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20061215

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061215

BERE Be: lapsed

Owner name: *SMITHKLINE BEECHAM P.L.C.

Effective date: 20061231

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20061216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071215